| NCT ID | NCT03313271 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jun Zhu |
| Condition | Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2017-05-17 |
| Primary Completion | 2027-05-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2017-05-17 with a primary completion date of 2027-05-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Lymphoma is the most common hematologic tumor. It is derived from lymphoid tissue, including Hodgkin's lymphoma(HL) and non Hodgkin's lymphoma(NHL). The treatment of lymphoma includes chemotherapy, radiotherapy, stem cell transplantation, targeted therapy and surgery etc. With the progress of treatment, the survival rate of lymphoma patients has been improved. But the 5 year survival rate of lymphoma in China is shorter than that in United States. The reason is that there is still a gap between China and the United States in disease screening, diagnosis and treatment. Observational studies, especially cohort studies, are important tools for understanding disease progression, treatment, and prognosis in the real world. Observational cohort studies which involve over 500 patients are currently launched by South Korea and the United States. China, which has more patients, doesn't have a cohort of patients with lymphoma. So the primary objective of this study was to establish an observational cohort of patients with lymphoma in China and follow up the patients for a long period of time to provide basic support for clinical research and drug development, and continuously improve patient outcomes and quality of life. The secondary objective is to collect information about diagnosis, treatment, follow-up and prognosis of lymphoma.
Eligibility Criteria
Inclusion Criteria: * The disease was diagnosed by Hodgkin's or non Hodgkin's lymphoma * 18 years of age or older at diagnosis * The diagnosis was confirmed within 6 months before admission * Informed consent was obtained Exclusion Criteria: * There are no special exclusion criteria in this study
Contact & Investigator
Jun Zhu, Ph D
PRINCIPAL INVESTIGATOR
Peking University Cancer Hospital & Institute
Frequently Asked Questions
Who can join the NCT03313271 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03313271 currently recruiting?
Yes, NCT03313271 is actively recruiting participants. Contact the research team at songyuqin622@163.com for enrollment information.
Where is the NCT03313271 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT03313271 clinical trial?
NCT03313271 is sponsored by Jun Zhu. The principal investigator is Jun Zhu, Ph D at Peking University Cancer Hospital & Institute. The trial plans to enroll 5,000 participants.